XENE (37) AMLX (38) ACAD (66) IRON (54) ⌘ Pro Terminal →

Organon & Co. (OGN) — RQD Stock Rating Cockpit

$13.81 +0.22% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Organon & Co. (OGN) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $3.63B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OGN)Realized 20D OHLCV Swing Band: ±1.8%

RSI-14 MOMENTUMBULLISH MOMENTUM

67.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE99% OF RANGE

L: $6$13.81H: $14

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (53% profit margin and healthy balance-sheet cushion).

Factor Grade: ARQD 18 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on OGN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (90)

24.9% ROIC with 53.3% gross margin and 14.83% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

25/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like OGN

✓Strong cash generator (53% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (OGN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.23%⚡ TESTING RESISTANCE

2026-10-30O $13.83H $13.84L $13.81C $13.81VOL 1.85M

RES: $13.86SUP: $13.75SMA50: $13.74SMA200: $11.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OGN Butterfly Map → + Track OGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

12.8%/yr Implied 5Y Growth

vs. -2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OGN)

Health Care Rank #180 of 1016 ⚔️ XENE vs OGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OGN vs. XENE, AMLX, ACAD, IRON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Organon & Co. (OGN) ranks #180 by composite RQD confidence (61/100, grade C-) and #191 by equity capitalization ($3.63B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. ACAD currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with OGN at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OGN ACTIVE Organon & Co.	C-	61/100	19.4x	53.3%	24.9%	+0.22%	$3.63B	Benchmark Subject
XENE Xenon Pharmaceuticals Inc.	D-	37/100	—	—	-35.0%	+3.30%	$3.64B	/xene-vs-ogn →
AMLX Amylyx Pharmaceuticals Inc.	D-	38/100	—	—	-35.0%	+2.17%	$3.60B	/amlx-vs-ogn →
ACAD ACADIA Pharmaceuticals Inc.	C+	66/100	9.1x	91.7%	7.9%	+2.17%	$3.58B	/acad-vs-ogn →
IRON Disc Medicine Inc.	D+	54/100	—	—	-27.5%	-0.43%	$3.68B	/iron-vs-ogn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001821825

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Organon & Co. (OGN) reported GAAP revenue of $6.22B (-2.9% vs. FY2024 revenue of $6.40B , and -0.8% cumulative change since FY2023) , GAAP net income of $187.0M, operating cash flow of $700.0M, and free cash flow of $538.0M (-29.6% YoY). On the balance sheet, OGN closed FY2025 with $12.87B in total assets against $8.63B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.22B	$187.0M	$700.0M	$538.0M	$12.87B	$8.63B
FY2024 (FY)	2024-12-31	$6.40B	$864.0M	$939.0M	$764.0M	$13.10B	$8.86B
FY2023 (FY)	2023-12-31	$6.26B	$1.02B	$799.0M	$799.0M	—	—

3. OGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Organon & Co. (NYSE: OGN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $13.81 (+0.22% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, OGN ranks #180 in composite RQD confidence.

How does OGN compare to XENE and AMLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGN carries a Roarable C- (61/100 RQD), trailing P/E of 19.4x, gross margin of 53.3%, and ROIC of 24.9%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.64B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OGN?

Per OGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821825), Organon & Co. generated $6.22B in revenue (-2.9% YoY), $187.0M in net income, and $538.0M in free cash flow against $12.87B in total assets and $8.63B in total debt. Key quantitative strengths: Strong cash generator (53% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OGN trading relative to its 50-day, 200-day, and 52-week technical levels?

OGN last traded at $13.81 (+0.22% on volume of 2,510,242 shares), positioning the stock +0.51% above its 50-day simple moving average ($13.74) and +19.88% above its 200-day simple moving average ($11.52). Across its 52-week range of $5.69 to $13.84, OGN sits at the 99.6% percentile with a 14-day RSI of 67.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($13.56 to $14.06).

OGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell OGN stock right now?

Organon & Co. (OGN) currently earns a Roarable Rating of C- (Hold — HOLD) with 61/100 RQD Confidence. Solid 53% profit margin (25% return on capital), mixed timing at 19x P/E—hold if owned, no rush to chase.

What is OGN's 12-month price target and RQD AI Jury consensus?

OGN's 12-month base price target is $14 (range $10.92 to $16.52), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: OGN RQD Cockpit OGN 12M Forecast OGN Earnings & Move OGN Dividends & DRIP OGN Insiders & 13F OGN Whale Options OGN Profit Sankey OGN News & Why